中生收购礼新说明会现场，秦莹否认默沙东退货传言

MedTrend医趋势2025-07-17

7月17日上午10点30-11点40，中国生物制药就收购礼新医药在香港召开说明会，中国生物制药董事会主席谢其润女士与礼新医药创始人、董事长兼首席执行官为秦莹博士出席现场。当下，市场关注点无疑是中生为何要并购礼新？以及传出的默沙东退货话题。现场，两位负责人也分别作出解释。关于提到的默沙东退货问题，现场礼新医药创始人、董事长兼首席执行官为秦莹博士提到：“礼新与默沙东的合作根据许可协议在正常有序地推进中...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2552248620?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-17 18:11","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2552248620","market":"us","top_or_hot":-1,"title":"中生收购礼新说明会现场，秦莹否认默沙东退货传言","media":"MedTrend医趋势","content":"<div>\n<p>7月17日上午10点30-11点40，中国生物制药就收购礼新医药在香港召开说明会，中国生物制药董事会主席谢其润女士与礼新医药创始人、董事长兼首席执行官为秦莹博士出席现场。当下，市场关注点无疑是中生为何要并购礼新？以及传出的默沙东退货话题。现场，两位负责人也分别作出解释。关于提到的默沙东退货问题，现场礼新医药创始人、董事长兼首席执行官为秦莹博士提到：“礼新与默沙东的合作根据许可协议在正常有序地推进中...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717183708a450e74a&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中生收购礼新说明会现场，秦莹否认默沙东退货传言</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中生收购礼新说明会现场，秦莹否认默沙东退货传言\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-17 18:11 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717183708a450e74a&s=b><strong>MedTrend医趋势</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月17日上午10点30-11点40，中国生物制药就收购礼新医药在香港召开说明会，中国生物制药董事会主席谢其润女士与礼新医药创始人、董事长兼首席执行官为秦莹博士出席现场。当下，市场关注点无疑是中生为何要并购礼新？以及传出的默沙东退货话题。现场，两位负责人也分别作出解释。关于提到的默沙东退货问题，现场礼新医药创始人、董事长兼首席执行官为秦莹博士提到：“礼新与默沙东的合作根据许可协议在正常有序地推进中...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717183708a450e74a&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0238689110.USD","symbol_name":"贝莱德环球动力股票基金","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717183708a450e74a&s=b","article_id":"2552248620","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717183708a450e74a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2552248620","pubTimestamp":1752747074,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"7月17日上午10点30-11点40，中国生物制药就收购礼新医药在香港召开说明会，中国生物制药董事会主席谢其润女士与礼新医药创始人、董事长兼首席执行官为秦莹博士出席现场。以及传出的默沙东退货话题。现场，两位负责人也分别作出解释。随后，中国生物制药宣布与礼新医药签署股权投资及战略合作协议。而中国生物制药也一直关注礼新医药，目前礼新医药已建成全球领先的抗体发现和ADC技术平台，是全市场唯一同时被MNC认可的双抗+ADC平台。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0238689110.USD":"贝莱德环球动力股票基金","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","SBHMY":"中国生物制药ADR","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","SG9999002224.SGD":"Allianz Global High Payout SGD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4516":"特朗普概念","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","BK4559":"巴菲特持仓","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4588":"碎股","BK4550":"红杉资本持仓","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","01177":"中国生物制药","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","SG9999014559.SGD":"United Income Focus Trust Dis SGD","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","MRK":"默沙东","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","SG9999002232.USD":"Allianz Global High Payout USD"},"translate_title":"At the briefing meeting on Zhongsheng's acquisition of Lixin, Qin Ying denied the rumors of Merck's return","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":0.9,"SBHMY":0.9,"MRK":1},"content_text":"7月17日上午10点30-11点40，中国生物制药就收购礼新医药在香港召开说明会，中国生物制药董事会主席谢其润女士与礼新医药创始人、董事长兼首席执行官为秦莹博士出席现场。当下，市场关注点无疑是中生为何要并购礼新？以及传出的默沙东退货话题。现场，两位负责人也分别作出解释。关于提到的默沙东退货问题，现场礼新医药创始人、董事长兼首席执行官为秦莹博士提到：“礼新与默沙东的合作根据许可协议在正常有序地推进中，现在外界有谣言，没有默沙东那边准许，不方便对外公布太多相关产品进展信息，如果有最新消息会尽快告诉大家。”针对中生为何要并购礼新话题，中国生物制药董事会主席谢其润女士提到：“这场缘分主要来自c轮的领投和ccr8靶点的LM-108药物研发的合作。”2024年10月18日，礼新医药宣布完成3亿元人民币C1轮融资，募集资金用于加快推进临床管线药物开发和创新平台建设。根据增资认购协议，中国生物制药作为本轮融资领投方，向礼新医药支付1.42亿元人民币，取得本次交易后礼新医药4.91%的股权。随后，中国生物制药宣布与礼新医药签署股权投资及战略合作协议。集团以自筹资金入股礼新医药，并就LM-108及未来潜在的多个创新双特异性抗体或抗体偶联药物(ADC)在中国大陆地区达成战略合作。提及这轮投资，礼新医药创始人、董事长兼首席执行官为秦莹博士表示：“是资本寒冬下的雪中送炭。”而中国生物制药也一直关注礼新医药，目前礼新医药已建成全球领先的抗体发现和ADC技术平台，是全市场唯一同时被MNC（阿斯利康、默沙东）认可的双抗+ADC平台。现有研发平台包括：包括肿瘤微环境特异性抗体开发平台 (LM-TME)、针对难成药靶点的抗体开发平台（LM-Abs）、新一代抗体偶联药物平台（LM-ADC）以及免疫细胞衔接器平台（LM-TCE）。目前，重磅产品LM-299（PD-1/VEGF双抗）、LM-305（GPRC5D ADC）、LM-108（CCR8单抗）、LM-302（Claudin 18.2 ADC）等8项资产正在开展临床，还有约20个项目处在临床前研究阶段。这些均为具有全球FIC或BIC潜力与国际化潜力的创新药物，而收购将进一步强化中国生物制药在前沿分子类型和肿瘤免疫领域的研发能力，加速全面创新发展。在现场，礼新医药创始人、董事长兼首席执行官为秦莹博士也特意提到几款重磅管线，这些新纳入的多项优质资产将极大地丰富中国生物制药现有肿瘤管线。LM-299（PD-1/VEGF双抗）：潜在BIC，目前正在中国进行I期临床试验。LM-305（GPRC5D ADC）：潜在FIC，目前正在全球进行I期临床试验。LM-108（CCR8单抗）：潜在FIC，目前正在中国进行II期注册临床试验，全球研发进度第一。LM-302（Claudin 18.2 ADC）：潜在FIC，目前正在中国进行III期注册临床试验。此外，此次收购，中国生物制药董事会主席谢其润女士表示：“礼新医药58人，包括所有核心团队成员将继续留任，进一步开发具备国际竞争力的分子。”","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2552248620","isCrawlerRequest":true}